Relevant bibliographies by topics / Drug related problems (DRPs)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Drug related problems (DRPs)'

Author: Grafiati
Published: 4 June 2021
Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drug related problems (DRPs).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Drug related problems (DRPs)"

1

Nguyen, Thao H., Vy T. T. Le, Dung N. Quach, Han G. Diep, Nguyet K. Nguyen, Anh N. Lam, Suol T. Pham, Katja Taxis, Thang Nguyen, and Phuong M. Nguyen. "Drug-Related Problems in Prescribing for Pediatric Outpatients in Vietnam." Healthcare 9, no. 3 (March 14, 2021): 327. http://dx.doi.org/10.3390/healthcare9030327.

Full text
Abstract:
Background: Our study was conducted to determine the prevalence of drug-related problems (DRPs) in outpatient prescriptions, the impact of DRPs on treatment efficacy, safety, and cost, and the determinants of DRPs in prescribing for pediatric outpatients in Vietnam. Methods: A retrospective cross-sectional study was conducted on pediatric outpatients at a pediatric hospital in Can Tho, Vietnam. DRPs were classified according to the Pharmaceutical Care Network Europe classification (PCNE) of 2020. The study determined prevalence of DRPs and their impacts on efficacy, safety, and cost. Multivariate regression was used to identify the determinants of DRPs. Results: The study included 4339 patients (mean age 4.3, 55.8% male), with a total of 3994 DRPs, averaging 0.92 DRP/prescription. The proportion of prescriptions with at least one DRP was 65.7%. DRPs included inappropriate drug selection (35.6%), wrong time of dosing relative to meals (35.6%), inappropriate dosage form (9.3%), inappropriate indication (7.1%), and drug-drug interactions (0.3%). The consensus of experts was average when evaluating each aspect of efficiency reduction, safety reduction, and treatment cost increase, with Fleiss’ coefficients of 0.558, 0.511, and 0.541, respectively (p < 0.001). Regarding prescriptions, 50.1% were assessed as reducing safety. The figures for increased costs and decreased treatment effectiveness were 29.0% and 23.9%, respectively. Patients who were ≤2 years old were more likely to have DRPs than patients aged 2 to 6 years old (OR = 0.696; 95% CI = 0.599–0.809) and patients aged over 6 years old (OR = 0.801; 95% CI = 0.672–0.955). Patients who had respiratory system disease were more likely to have DRPs than patients suffering from other diseases (OR = 0.715; 95% CI = 0.607–0.843). Patients with comorbidities were less likely to have DRPs than patients with no comorbidities (OR = 1.421; 95% CI = 1.219–1.655). Patients prescribed ≥5 drugs were more likely to have DRPs than patients who took fewer drugs (OR = 3.677; 95% CI = 2.907–4.650). Conclusion: The proportion of prescriptions in at least one DRP was quite high. Further studies should evaluate clinical significance and appropriate interventions, such as providing drug information and consulting doctors about DRPs.
APA, Harvard, Vancouver, ISO, and other styles
2

Repp, Kristin L., Charles Hayes, T. Mark Woods, Keith B. Allen, Kevin Kennedy, and Michael A. Borkon. "Drug-Related Problems and Hospital Admissions in Cardiac Transplant Recipients." Annals of Pharmacotherapy 46, no. 10 (October 2012): 1299–307. http://dx.doi.org/10.1345/aph.1r094.

Full text
Abstract:
Background: Drug-related problems (DRPs) in the general population account for 15% of all hospital admissions, of which approximately 30% are preventable. Cardiac transplant patients may be at increased risk for DRPs because of their complicated medication regimens that include drugs with a narrow therapeutic index. Objective: To determine the incidence and praventability of DRPs causing hospital admission in cardiac transplant patients at a single institution. Methods: Between November 2009 and January 2010, a prospective longitudinal study investigated the incidence and preventability of DRPs in a single cardiac transplant center. Three independent reviewers used validated scoring systems to determine the incidence and preventability of drug-related hospital admissions. DRPs were classified by type, pharmacologic class, and impact on length of stay. Results: During the 3-month study period, 48 cardiac transplant patients were hospitalized. DRPs accounted for 40% (19/48) of these admissions and 58% (11/19) were adjudicated to be preventable. Common DRPs included supratherapeutic (32%) and subtherapeutic (16%) dosage, adverse drug reaction (32%), drug interaction (5%), and nonadherence (5%). Pharmacologic classes implicated included immunosuppressant (63%), antimicrobial (11%), electrolyte/fluid (11%). and anticoagulant (5%). Average length of stay in drug-related compared to non-drug-related admissions was 11.4 versus 8.5 days (p = 0.458). When annualized, 44 hospitalizations or 500 hospital days may have been prevented. Conclusions: Hospital admissions following cardiac transplantation are often drug related (40%) and preventable (58%). Incorporating this insight into the multidisciplinary transplant team may improve outcomes, assist in meeting national quality mandates by the United Network for Organ Sharing and Centers for Medicare Services, and lead to new benchmarks for transplant centers.
APA, Harvard, Vancouver, ISO, and other styles
3

Meng, Long, Can Qu, Xia Qin, Huali Huang, Yongsheng Hu, Feng Qiu, and Shusen Sun. "Drug-Related Problems among Hospitalized Surgical Elderly Patients in China." BioMed Research International 2021 (February 15, 2021): 1–6. http://dx.doi.org/10.1155/2021/8830606.

Full text
Abstract:
There is a lack of data on drug-related problems (DRPs) among elderly patients from surgical departments. The current study is aimed at identifying and categorizing types of DRPs and assessing the severities of the DRPs. Medication orders for hospitalized patients aged ≥65 years from six surgery departments were reviewed to determine DRPs over 6 months in a tertiary teaching hospital of Chongqing, China. DRPs were classified based on the Pharmaceutical Care Network Europe classification V8.02. The severity ratings of the DRPs were assessed using the National Coordinating Council for Medication Error Reporting and Prevention classification. A total of 53,231 medication orders from 1,707 elderly patients were reviewed, and 1,061 DRPs were identified. Treatment safety (44.9%) was the most common DRP type. Drug selection (43.1%) and dose selection (43.1%) were the major causes of DRPs. A total of 75.1% of the DRPs were classified into severity categories B to D (causing no or potential harm), and 24.9% were classified as categories E to H (causing actual harm). DRPs are common in hospitalized elderly surgical patients. Pharmacists should provide medication order reviews in this vulnerable patient population.
APA, Harvard, Vancouver, ISO, and other styles
4

Ramadaniati, Hesty U., Yusi Anggriani, Vonny M. Wowor, and Alvina Rianti. "DRUG-RELATED PROBLEMS IN CHRONIC KIDNEYS DISEASE PATIENTS IN AN INDONESIAN HOSPITAL: DO THE PROBLEMS REALLY MATTER?" International Journal of Pharmacy and Pharmaceutical Sciences 8, no. 12 (December 1, 2016): 298. http://dx.doi.org/10.22159/ijpps.2016v8i12.15193.

Full text
Abstract:
<p><strong>Objective: </strong>To identify and evaluate drug-related problems (DRPs) in patients with chronic kidney disease (CKD).</p><p><strong>Methods: </strong>A prospective observational three-month study was conducted in adult patients with CKD hospitalized in five general medical wards and one intensive cardiac care unit in a major teaching hospital in Indonesia. Principal researcher (pharmacist) identified the occurrence of DRPs through the direct patient interview, discussion with nurses and assessment of patients’ medication charts and medical records. The identified DRPs were validated by a senior pharmacist and classified using Pharmaceutical Care Network Europe/PCNE classification scheme for DRP V6.2. Descriptive analysis was applied for demographic data, drug utilization and DRP profiles.</p><p><strong>Results: </strong>There were 105 patients who met the inclusion criteria and 80% of these patients had end-stage renal disease. A total of 2404 medication orders were reviewed and 1026 DRPs were identified. Potential DRPs accounted for around two-thirds of the cases. The rate of overall DRPs was 42.7 DRPs per 100 medication orders and each patient in the study experienced approximately ten DRPs during their hospitalization. Treatment effectiveness and adverse reaction domains contributed to the majority of DRPs primary domains for problems. Drugs for cardiovascular diseases and drugs for correcting electrolyte imbalance were most commonly implicated in DRP incidence.</p><p><strong>Conclusion: </strong>This study uncovered higher rate of DRPs experienced by each patient compared to other CKD studies. There were variations of DRP types when comparing with similar studies. Pharmacists’ competencies to identify, prevent and resolve DRPs are vital measures to improve clinical outcomes in CKD patients.</p>
APA, Harvard, Vancouver, ISO, and other styles
5

Kibsdal, Karina Porsborg, Sabina Andersen, Parisa Gazerani, and Hanne Plet. "Rates and correlates of pharmacotherapy-related problems among psychiatric inpatients: a representative Danish study." Therapeutic Advances in Psychopharmacology 10 (January 2020): 204512532095712. http://dx.doi.org/10.1177/2045125320957120.

Full text
Abstract:
Background: Drug related problems (DRPs) occur frequently among psychiatric patients due to common prescribing errors and complex treatment schedules. Clinical pharmacists (CPs) are thought to play an important role in preventing DRPs and, consequently, to increasing the quality of inpatient care. There is, however, limited information available on DRPs within the psychiatric field in Denmark. The aim of this study was to identify rates and correlates of pharmacotherapy-related problems among psychiatric inpatients in a Danish psychiatric hospital. Methods: A retrospective descriptive study was conducted by two CPs and data were obtained from the medical records available in two psychiatric wards. Chart-reviews were conducted for the period of June 2015 to February 2017. The analyses focussed on the prevalence of DRP categories, implementation and acceptance rates, and drugs associated with the DRPs. Extracted data were discussed with the wards’ physicians and registered in a DRP-database. Results: In total, 607 medical records were reviewed and, on average, 2.5 DRPs per medication review were found. There was a positive correlation between the number prescribed drugs and the average number of DRPs. The most frequent categories of DRPs were ‘drug dosage’, ‘inappropriate drug’ and ‘interactions’. The drugs represented most frequently in DRPs were olanzapine, quetiapine and pantoprazole. The overall acceptance rate was 49% with 33% of those implemented clinically. Conclusion: DRPs were commonly observed among psychiatric patients, particularly in those with multiple prescriptions, in relation to drugs dosage, inappropriate prescriptions and drug interactions. Particular attention must be paid to olanzapine, quetiapine and pantoprazole. Strategies to minimise DRPs among psychiatric patients are warranted and CPs can play an important role.
APA, Harvard, Vancouver, ISO, and other styles
6

TV, Niveditha, Abhishek Pradhan, and A. R. Shabaraya. "Drug Related Problems in Geriatric Patients with Inappropriate Medication Use." International Journal of Research and Review 8, no. 5 (June 3, 2021): 487–96. http://dx.doi.org/10.52403/ijrr.20210559.

Full text
Abstract:
Drug related problem (DRP) is an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes. Nowadays geriatric patients are at high risk of DRPs due to polypharmacy and altered physiology or due to older patients cannot manage their medication. DRPs also could arise from age related chronic diseases. The DRPs following hospital discharged cases also increased in elder people with chronic disease. Geriatric patients faces DRPs include inappropriate use of medication, polypharmacy, noncompliance, ADRs, drug–drug interaction, etc. Geriatric patients require more care because DRPs sometimes leads to hospital admission days, cost of the medication, increased morbidity rate and reduce the quality of life etc. So these category people need special consideration while selecting the drug therapy and its pattern. Like other health care services this special category of patients’ needs good care or services from a team of health care professionals including clinical pharmacists. This review article aims to understand the risk factors and different types of DRPs that are facing by the elderly people due to inappropriate medication use and pharmaceutical care by clinical pharmacists. Keywords: Geriatric patients, Polypharmacy, Non-compliance, and Drug related problems.
APA, Harvard, Vancouver, ISO, and other styles
7

Wucherer, D., J. R. Thyrian, T. Eichler, J. Hertel, I. Kilimann, S. Richter, B. Michalowsky, et al. "Drug-related problems in community-dwelling primary care patients screened positive for dementia." International Psychogeriatrics 29, no. 11 (August 7, 2017): 1857–68. http://dx.doi.org/10.1017/s1041610217001442.

Full text
Abstract:
ABSTRACTBackground:Older people have a higher risk of drug-related problems (DRPs). However, little is known about the prevalence of DRPs in community-dwelling people who screened positive for dementia. Our study aimed to determine (1) the prevalence and types of DRPs and (2) the socio-demographic and clinical variables associated with DRPs in people screened positive for dementia in primary care.Methods:The Dementia: life- and person-centered help in Mecklenburg-Western Pomerania (DelpHi-MV) study is a general practitioner (GP)-based cluster-randomized controlled intervention study to implement and evaluate an innovative concept of collaborative dementia care management in the primary care setting in Germany. Medication reviews of 446 study participants were conducted by pharmacists based on a comprehensive baseline assessment that included a computer-based home medication assessment. ClinicalTrials.gov Identifier: NCT01401582.Results:A total of 1,077 DRPs were documented. In 414 study participants (93%), at least one DRP was detected by a pharmacist. The most frequent DRPs were administration and compliance problems (60%), drug interactions (17%), and problems with inappropriate drug choice (15%). The number of DRPs was significantly associated with the total number of drugs taken and with a formal diagnosis of a mental or behavioral disorder.Conclusions:Degree of cognitive impairment (MMSE defined) and formal diagnosis of dementia were not risk factors for an increased number of DRPs. However, the total number of drug taken and the presence of a diagnosis of mental and behavioral disorders were associated with an increased total number of DRPs.
APA, Harvard, Vancouver, ISO, and other styles
8

Haris kurniawan, Andi. "PHARMACIST INTERVENTION ON THE INCIDENCE OF DRUG RELATED PROBLEMS IN PATIEN WITH CHRONIC KIDNEY DISEASE IN RSU PKU MUHAMMADIYAH BANTUL." INPHARNMED Journal (Indonesian Pharmacy and Natural Medicine Journal) 4, no. 2 (December 4, 2020): 1. http://dx.doi.org/10.21927/inpharnmed.v4i2.1253.

Full text
Abstract:
<pre>Chronic kidney disease (CKD) is a disease that often appears in various countries. Progressive decline in kidney function in patients with chronic kidney disease can lead to unexpected events from drug use, due to decreased kidney function in excreting the drug and its metabolites in addition to the co-morbidities that often arise. Drug Related Problems (DRPs) is one of the problems that can arise from a treatment. Drug Related Problems (DRPs) in addition to impacting the effectiveness and safety of a treatment can also cause morbidity, mortality and treatment costs incurred by the patient. This study aims to look at the picture of DRPs that occur in CKD patients and the effect of pharmacist intervention on DRPs in PKU Muhammadiyah Hospital Bantul by comparing DRPs that arise before and after pharmacist intervention. This research is descriptive with an observational cohort design. Data was collected prospectively in a cohort to see DRPs drawings and the influence of pharmacist interventions on the incidence of DRPs in inpatient CKD patients at PKU Muhammadiyah Hospital in Bantul in the period August-October 2017. The DRPs category followed the PCNE V7.0 DRP classification, recorded DRPs in the problem category for 19 cases (45.2%) and the category of loading were 24 cases (57.1%). The most drug related problems were found to be non-optimal therapy (28.6%), the time / interval of drug administration (26.8%), the combination of drugs with drugs (16.7%) and there were indications of no drugs (11.9% ). Pharmacists intervened with the incidence of DRPs found, pharmacists intervened in the form of changing instructions for using drugs (30.7%), giving information / recommendations to prescribers (16.7%) and providing education to patients (11.9%). Pharmacist intervention can prevent or overcome the DRPs found. Conclusions in this study there are still DRPs that occur in inpatient CKD patients. The involvement of pharmacists can prevent or reduce the incidence of DRPs and ensure efficient, effective and safe drug therapy.</pre>
APA, Harvard, Vancouver, ISO, and other styles
9

Yismaw, Malede Berihun, Haileyesus Adam, and Ephrem Engidawork. "Identification and Resolution of Drug-Related Problems among Childhood Cancer Patients in Ethiopia." Journal of Oncology 2020 (March 16, 2020): 1–9. http://dx.doi.org/10.1155/2020/6785835.

Full text
Abstract:
Background. Even though medications play a major role in the cure, palliation, and inhibition of disease, they also expose patients to drug-related problems. Drug-related problems are frequent and may result in reduced quality of life, morbidity, and mortality. Objectives. The study was aimed to identify, characterize, and resolve drug-related problems in the Pediatric Hematology/Oncology ward of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Methods. A prospective observational study was conducted from 25 June to 25 October 2018 to assess DRPs on patients admitted at the pediatric hematology/oncology ward of Tikur Anbessa Specialized Hospital, which is the highest level governmental tertiary care hospital in Ethiopia. Data were obtained from patients’ medical charts, physicians, patients/caregivers, pharmacists, and nurses. All the collected data were entered and analyzed using the Statistical Package for the Social Sciences version 25e. Descriptive statistics were used to represent the data. Results. Among the total 156 participants, DRPs were identified in 68.6% of the study subjects. Dosing problems which include dosage too low and high were the top ranking (39.3%) of all DRPs followed by needs additional therapy (27.2%) and nonadherence (14.0%). Systemic anti-infectives were the most common class of drugs involved in DRPs. Trimethoprim-sulfamethoxazole, methotrexate, vincristine, ondansetron, and metoclopramide were frequently involved in DRPs. The addition of drugs and change in drug dose were the two most proposed intervention types. Among the proposed interventions, 223 (92.15%) were fully accepted, 9 (3.72%) partially accepted, and 10 (4.13%) not accepted. Conclusion. DRPs are common among Pediatric Hematology/Oncology ward patients. The hospital should develop a pediatric dosing chart for the commonly prescribed medications to prevent drug-related morbidity and mortality. The integration of clinical pharmacists can mitigate risks associated with DRPs.
APA, Harvard, Vancouver, ISO, and other styles
10

Hale, Cory M., Jeffrey M. Steele, Robert W. Seabury, and Christopher D. Miller. "Characterization of Drug-Related Problems Occurring in Patients Receiving Outpatient Antimicrobial Therapy." Journal of Pharmacy Practice 30, no. 6 (January 23, 2017): 600–605. http://dx.doi.org/10.1177/0897190016688771.

Full text
Abstract:
Background: Despite the numerous benefits of outpatient parenteral antimicrobial therapy (OPAT), appreciable risks of drug-related problems (DRPs) exist. No studies to date comprehensively assess DRPs in this population. Objectives: Objectives of this study were to (1) characterize the frequency and types of DRPs experienced by patients discharged on OPAT and (2) determine the fraction of adverse drug reactions (ADRs) resulting in hospital readmission or emergency department (ED) presentation and changes in therapy. Methods: This was a retrospective chart analysis evaluating consecutive adult patients discharged on OPAT between May 2015 and October 2015. Patients were assessed for the presence of DRPs until the cessation of antimicrobial treatment, including oral step-down therapy. The outcome of each ADR was recorded, including those resulting in hospital readmissions, presentation to the ED, or changes in antimicrobials. Results: Among 144 patients discharged on OPAT, 199 DRPs occurred in 91 (63.2%) patients. Harm and potential impaired efficacy occurred in 76.9% and 23.1%, respectively. The ADRs comprised 59% of DRPs, occurring in 44.4% of patients. The second most common DRP type was drug interactions (DIs), accounting for 22.6% of DRPs. Rifampin, fluoroquinolones, and daptomycin had the highest frequencies of preventable DRPs in the form of DIs, whereas cephalosporins had the fewest DRPs. Approximately 26% of ADRs caused changes in therapy and 9% resulted in hospital readmission or ED utilization. Conclusion: DRPs with the potential to cause patient harm or impair treatment efficacy often occur with OPAT, most commonly ADRs and DIs. Enhanced monitoring and transitions of care management may reduce the incidence of these DRPs.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Drug related problems (DRPs)"

1

Ibrahim, N. "Drug-related problems (DRPs) in children with kidney disease." Thesis, University College London (University of London), 2014. http://discovery.ucl.ac.uk/1448344/.

Full text
Abstract:
Introduction: Medicines are used with the intention of benefitting from their effect. The effects of medicines can also be undesirable and potentially lead to harm. A drug-related problem (DRP) is a term used to describe problem(s) that exist in the use of medicines. There remains a distinct paucity of data on the epidemiology of DRPs in children with kidney disease. Aim: To investigate the epidemiology of DRPs in children with kidney disease in clinical practice at tertiary Paediatric Nephrology units. Methods: Study 1: Prospective observational study on the characteristics of DRPs in hospitalised children with kidney disease. Study 2: Randomised control trial on clinical pharmacist (CP) interventions in resolving DRPs on the renal outpatient clinic. Results: Study 1: A total of 127 patients were recruited and a total of 203 DRPs were identified. The incidence of DRP was 51.2% (95% CI 43.2-60.6%) of patients reviewed by the CPs. The number of medicines prescribed per child was the only significant risk factor for the occurrence of DRPs (OR 1.06, 95% CI 1.02-1.10, p=0.002). The majority of DRPs were minor in clinical significance (68%, n=138/203). The predominant DRPs were sub-optimal drug effect. These DRPs were associated with drug selections and dosage errors. Study 2: A total of 100 patients were recruited (Control n=53, Intervention n=47). The trial showed no effect of intervention in the resolution of active DRPs (p=0.96) between the Control and Intervention arms. Conclusion: DRPs are common in children with kidney disease and necessitate a comprehensive approach to their identification and resolution. Their characteristics in both settings are different even though the majority of them shared a similar level of clinical significance. Further research is required to evaluate the effectiveness of pharmacists’ intervention in resolving DRPs at the outpatient clinics.
APA, Harvard, Vancouver, ISO, and other styles
2

Malfará, Marcia Regina Medeiros. "Avaliação do impacto das intervenções do farmacêutico clínico na prevenção de problemas relacionados à farmacoterapia em um centro de terapia intensiva pediátrico de hospital de ensino." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/17/17144/tde-24042018-165341/.

Full text
Abstract:
Erros de medicação e eventos adversos relacionados a medicamentos são comuns em pacientes hospitalizados. O risco de ocorrer problemas com a população pediátrica é cerca de três vezes maior do que com a população adulta, especialmente em unidades de terapia intensiva, onde os pacientes são submetidos a grande número de prescrições de medicamentos intravenosos, com baixo índice terapêutico e formas farmacêuticas adaptadas. A farmácia clínica tem como objetivo introduzir o farmacêutico clínico junto à equipe multidisciplinar de saúde no sentido de intervir, prevenindo problemas relacionados a medicamentos à farmacoterapia (PRF), otimizando-a e contribuindo para a segurança do paciente. O presente estudo teve como objetivo avaliar a implantação e o impacto das intervenções da farmácia clínica no Centro de Terapia Intensiva-Pediátrico (CTIP) do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP-USP). Trata-se de estudo prospectivo, observacional e descritivo que incluiu crianças de zero a dezoito anos, no período de um ano. Foi aplicada a ferramenta Failure Mode and Effects Analysis (FMEA - Análise dos Modos de Falha e seus Efeitos) no início do estudo para avaliar os riscos relacionados aos medicamentos no CTIP e orientar a atuação da farmácia clínica, em que o farmacêutico avaliou as prescrições diárias e realizou intervenções junto à equipe multidisciplinar. Foram acompanhadas 162 crianças e avaliadas 1586 prescrições com uma taxa de PRF de 12,42% (IC95% 10,50-14,04). Foram realizadas 197 intervenções com custo salvo de R$15.118,73. Os principais tipos de intervenções foram relacionados à indicação e necessidade do medicamento. A partir destas, os grupos foram divididos em pacientes com PRF e sem PRF. Foram detectadas diferenças significativas nas seguintes variáveis: peso, idade, tempo de internação, tempo de acompanhamento, custo total, custo salvo pelas intervenções, gravidade dos pacientes avaliada pelo escore PRISM e PELOD, quantidade total de medicamentos utilizados e quantidade de medicamentos potencialmente perigosos e endovenosos contínuos. Além disso, houve diferenças significativas na taxa de óbito e nas categorias diagnósticas entre os grupos. A implantação do serviço de farmácia clínica no CTIP mostrou impacto positivo na redução de riscos relacionados a todo o processo de utilização de medicamentos. As intervenções do farmacêutico clínico identificaram e preveniram PRF, promovendo o uso racional de medicamentos e contribuindo para a redução de custos associados à prescrição médica.
Medication errors and adverse events related to drugs are common in hospitalized patients. The potential risk for medication errors in pediatric patients is about three times higher than in adults, especially in intensive care units, where patients are subjected to a large number of intravenous drug prescriptions, with low therapeutic index and adapted pharmaceutical forms. Clinical pharmacy aims to introduce the clinical pharmacist in a multidisciplinary health team in order to intervene, preventing drug-related problems (DRPs) and optimize pharmacotherapy, contributing to patient safety. This study aimed to assess the implementation and the impact of clinical pharmacy interventions in the Pediatric Intensive Care Unit (PICU) of Hospital das Clinicas of Ribeirao Preto Medical School, University of São Paulo (HCFMRP-USP). This was a prospective, observational and descriptive study which included children from zero to eighteen years of age, over a one year period. Failure Mode and Effects Analysis Tool (FMEA) was applied at the beginning of the study to assess the risks related to medicines in the PICU and to guide clinical pharmacy work, where the pharmacist evaluated daily prescriptions and made interventions along with a multidisciplinary team. One thousand five hundred and eighty-six prescriptions of 162 children were assessed, and a DRPs rate of 12.42% (95% CI - 10.50 to 14.04) was found. One hundred ninety-seven interventions were performed, with a cost saving of R$ 15,118.73. The main types of interventions were related to indication and necessity of the drug. From these, the groups were divided in patients with DRPs and without DRPs. Significant differences were found in weight, age, time of hospitalization, time of follow-up, total cost, costs saved by interventions, severity of patients assessed by PRISM and PELOD scores, total amount of medications used, and number of potentially dangerous and continuous intravenous medications. In addition, there were significant differences in mortality rate and diagnostic categories between groups. The implementation of clinical pharmacy service in the PICU showed a positive impact on patients\' treatment. The clinical pharmacist interventions identified and prevented DRPs, promoting the rational use of medications and contributing to the reduction of costs associated with medical prescription.
APA, Harvard, Vancouver, ISO, and other styles
3

Mannheimer, Buster. "Drug-related problems with special emphasis on drug-drug interactions." Stockholm : Department of Clinical Science and Education, Karolinska Institutet, 2009. http://diss.kib.ki.se/2009/978-91-7409-602-6/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Al-Deagi, Fawzi A. A. "Drug-related problems in elderly patients." Thesis, Queen's University Belfast, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.318951.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Easton-Carter, Kylie 1973. "The consequences of drug related problems in paediatrics." Monash University, Dept. of Pharmacy Practice, 2001. http://arrow.monash.edu.au/hdl/1959.1/8988.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gordon, Karen Joyale. "Drug related problems in cardiovascular patients in primary care." Thesis, University College London (University of London), 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.269639.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Abramsson, Linnea. "PREVALENCE OF DRUG RELATED PROBLEMS STOPP/START in elderly people with dementia." Thesis, Umeå universitet, Farmakologi, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-157692.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Petropulos, Anthony J. A. (Anthony John Alexander). "Understanding the dynamics of drug-related problems in public housing and its surrounding neighborhood." Thesis, Massachusetts Institute of Technology, 1996. http://hdl.handle.net/1721.1/69362.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Koubaity, Majda. "Drug-Related Problems in Belgium: From community pharmacies to hospital: State of the situation and Impact." Doctoral thesis, Universite Libre de Bruxelles, 2019. https://dipot.ulb.ac.be/dspace/bitstream/2013/294510/3/TM.doc.

Full text
Abstract:
IntroductionDepuis plusieurs décennies, la pratique et les soins pharmaceutiques sont soumis à plusieurs changements en partie en raison de l’évolution de la société, des progrès de la recherche et de la mise sur le marché de nouveaux médicaments. La pratique du pharmacien a passée d’une délivrance centrée sur le médicament vers la délivrance centrée sur le patient notamment par la détection, l’intervention et la résolution des Problèmes Liés aux Médicaments (PLM).Certains patients atteints d’une condition médicale particulière, tels que les patients cancéreux, peuvent être soumis à des traitements lourds qui leurs sont nécessaires mais qui peuvent les rendre plus vulnérable à l’apparition d’un PLMObjectifsL'objectif de cette thèse était de mettre en évidence la proportion des PLM dans les pharmacies d’officines ainsi qu’à l'hôpital et d’évaluer les potentielles conséquences en milieu hospitalier.La première partie était composée de deux projets ;1) Traduction et adaptation de la classification du PCNE V6.2 à la pratique et au cadre juridique pharmaceutique belge en intégrant la validation du contenu et la fiabilité inter-évaluateur de la classification adaptée. 2) Étude pilote visant à évaluer la proportion de PLM des antidouleurs les plus utilisés en Belgique.La deuxième partie de cette thèse était composée de trois projets. 1) Quantification et classification des réadmissions des PLM des patients cancéreux réadmis dans les 30 jours et mise en évidence des facteurs de risque liés à ces réadmissions ;2) Évaluation des coûts liés aux réadmissions dues aux PLM et les potentielles économies de PLM évitables ;3) Détection des interactions médicamenteuses à partir de différentes sources disponibles au sein de la population cancéreuse réadmise lors du premier projet et évaluation de l’impact de ces interactions sur la survie des patients.MéthodeLa classification du PCNE V6.2 a été adaptée et traduite pour le contexte belge. Afin d’évaluer la validité du contenu, les pharmaciens académiques et d’officines ont évalué six critères, deux qui ciblaient le mode d’emploi (compréhensibilité, utilité) et quatre le formulaire d’encodage (pertinence, logique d’agencement, exhaustivité et redondance). Lors de leur pratique quotidienne, les pharmaciens ont appliqué l'outil adapté du PCNE afin d’évaluer si les instructions avaient été respectées et de quantifier le temps nécessaire pour résoudre un PLM. Par la suite, l’analyse des encodages des pharmaciens a permis d’estimer la fiabilité inter-évaluateurs. Le second projet était une étude pilote qui a permis aux étudiants de Master 2 d’encoder avec l’outil adapté du PCNE V6.2 les PLM détectés en officine par leur maître de stage. Les PLM impliquant les antidouleurs ont été extraits de la base de données initiale et ont été analysés.La deuxième partie s’est basée sur une étude rétrospective observationnelle de six mois dans deux établissements de soins Bruxellois :un hôpital général universitaire et un centre de référence en oncologie. Afin d’évaluer les PLM, une revue de médication de type 2b a été appliquée pour chaque patient réadmis aux urgences ou suite à une consultation médicale. La probabilité d’implication d’un PLM dans la réadmission a été évaluée à l’aide du système du Centre de surveillance de l'organisation mondiale de la santé d'Uppsala (OMS-UMC). La réception de la base de données des différents coûts liés à ces réadmissions a permis une estimation des coûts de réadmission de ces PLM pour chacun des deux établissements impliqués. Le caractère évitable d’un PLM a pu être évalué par l’utilisation du questionnaire de Schumock et al. Le dernier projet à évaluer les potentielles interactions médicamenteuses à l'aide des bases de données en ligne Lexicomp® et Epocrates®. Une analyse de survie de Kaplan-Meier et une analyse de Cox ont été effectuées pour évaluer le lien entre les variables interaction et survenue du décès.RésultatsL'adaptation de l’outil a permis l'ajout de 16 items. Une bonne validation du contenue a été obtenue suite à l’évaluation des pharmaciens académiques et des pharmaciens d’officine. Un total de 109 PLM a été encodé, avec un temps de résolution moyen de 5 min. Concernant la fiabilité inter-évaluateur, 74 items sur un ensemble de 83 ont montré une fiabilité élevée. L’étude pilote a permis de recueillir 15 952 PLM, dont 1 832 pour les antidouleurs, 3 200 interventions ont été produites afin de résoudre les PLM. La majorité des PLM ont été totalement ou partiellement résolus (77,2%).Lors de la seconde partie de la thèse, l’analyse des dossiers de patients cancéreux réadmis dans les 30 jours a révélé que 123 patients avaient été réadmis pour un PLM certain (4,9%), probable (49,6%) ou possible (45,5%). Les facteurs de risque mis en évidence étaient un faible score de Charlson, la polymédication et certaines chimiothérapies (préparations à base de Platine, les anthracyclines ou les vinca-alcaloides). Un montant total de 495 869,10 € a été mis en évidence pour les réadmissions dues aux PLM, avec une durée médiane d’hospitalisation de 7 jours. Les cancers prédominants liés à ces réadmissions étaient le poumon (19,5%) et le sein (17,9%). En se basant sur les diagnostiques des médecins, une part importante (71,5%) des réadmissions du aux PLM était liée aux effets indésirables de la chimiothérapie.Le troisième projet de la seconde partie de ce travail a inclus une population finale de 299 patients réadmis 30 jours après la sortie de l'hôpital en raison d’un PLM. Selon les bases de données en ligne, entre 78,9% et 80,9% des patients étaient réadmis avec au moins une interaction. En moyenne entre 1,6 et 2,3 interactions par patient ont été détectés pour Lexicomp® et Epocrates®. Les opioïdes (29,9%) suivis des anxiolytiques (15,8%) étaient les médicaments les plus souvent impliqués. Les effets indésirables les plus prédominants étaient les dépressions du système nerveux central (SNC) et les dépressions respiratoires. Des analyses de Kaplan-Meier ont montré une différence statistiquement significative sur la survenue du décès, entre les patients avec et sans interactions. Néanmoins, le décès ne semble pas être directement lié à la présence d'une interaction.ConclusionLa première partie a pu montrer que l’adaptation de l’outil au contexte francophone belge était fiable et avait une validité suffisante pour une utilisation quotidienne. La participation de 6 facultés belges a permis une implication nationale permettant d’obtenir une grande proportion de PLM (15 952) ;parmi eux, plus de 10% concernaient les antidouleurs dont la quasi-totalité ont été complètement résolus.Concernant la deuxième partie, environ 10% des réadmissions de patients cancéreux dans les 30 jours suivant leur dernier soin étaient liées à un PLM, parmi ces réadmissions 71,5% étaient liées à un effet indésirable. Le coût médian par réadmission était de 2 406,10 €. Les PLM évitables représentaient 7,3% dont le coût s’élevait à un total 27 938,61 €. L’évaluation des interactions a pu mettre en évidence une forte proportion de potentielles interactions liées aux traitements de patients cancéreux, néanmoins cela ne semble pas être lié à la survenue du décès.Ce travail a pu mettre en évidence la présence importante de PLM en officine et la volonté des pharmaciens d’officines belges à améliorer leur pratique. Néanmoins l’intégration d’un outil plus spécifique à la pratique officinale sur le terrain permettrait une adhésion plus complète et potentiellement une meilleure détection. La deuxième partie de ce travail a montré quelques facteurs de risque intéressants et l’importante présence d'interactions, qui demandent une potentielle vigilance chez les patients cancéreux afin de réduire les risques de réadmission dues aux PLM et les coûts associés. Cependant, une meilleure communication entre les professionnels de santé au sein de l’hôpital mais également avec les prestataires extérieurs tels que les médecins de famille et les pharmaciens d’officine, pourrait permettre un meilleur suivi et une diminution de ces réadmissions avec pour objectif d'améliorer la qualité de vie des patients.
Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie)
info:eu-repo/semantics/nonPublished
APA, Harvard, Vancouver, ISO, and other styles
10

Morningstar, Bridget A. "Examination of drug-related problems in Nova Scotia seniors with diabetes using the Pharmacare Database, 1993-1995." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape9/PQDD_0021/MQ49412.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Drug related problems (DRPs)"

1

Midlöv, Patrik, Tommy Eriksson, and Annika Kragh. Drug-related problems in the elderly. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2446-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tagliamonte, Alessandro, and Icro Maremmani, eds. Drug Addiction and Related Clinical Problems. Vienna: Springer Vienna, 1995. http://dx.doi.org/10.1007/978-3-7091-6901-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Midlöv, Patrik. Drug-related problems in the elderly. Dordrecht: Springer, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Treating drug problems. Hoboken, N.J: John Wiley & Sons, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Drug abuse and drug-related crimes: Some unresolved legal problems. Dordrecht: M. Nijhoff Publishers, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1959-, Scratchley David, and Royce James E, eds. Alcoholism and other drug problems. New York: Free Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Royce, James E. Alcoholism and other drug problems. New York: Free Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cooper, James W. Drug-related problems in geriatric nursing home patients. New York: Haworth Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Drug-related problems in geriatric nursing home patients. New York: Pharmaceutical Products Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Workshop on Alcohol and Drug-Related Problems in Micronesia (1989 Koror, Palau). Workshop on Alcohol and Drug-Related Problems in Micronesia: Report. Manila, Philippines: The Organization, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Drug related problems (DRPs)"

1

Schuckit, Marc A. "Prevention of Substance-Related Problems." In Drug and Alcohol Abuse, 349–61. Boston, MA: Springer US, 2000. http://dx.doi.org/10.1007/978-1-4757-3232-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Midlöv, Patrik, Tommy Eriksson, and Annika Kragh. "Errors, Problems, Events and Reactions on Medication." In Drug-related problems in the elderly, 91–100. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2446-6_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Parrino, M. W. "1st European Methadone Conference Opening Remarks." In Drug Addiction and Related Clinical Problems, 213–18. Vienna: Springer Vienna, 1995. http://dx.doi.org/10.1007/978-3-7091-6901-8_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Midlöv, Patrik, Tommy Eriksson, and Annika Kragh. "Aging and Drugs." In Drug-related problems in the elderly, 1–7. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2446-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Midlöv, Patrik, Tommy Eriksson, and Annika Kragh. "Strategies and Interventions for Improvement." In Drug-related problems in the elderly, 119–27. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2446-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Midlöv, Patrik, Tommy Eriksson, and Annika Kragh. "Summary and Perspectives." In Drug-related problems in the elderly, 129–32. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2446-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Midlöv, Patrik, Tommy Eriksson, and Annika Kragh. "Physiological Alterations with Aging." In Drug-related problems in the elderly, 9–19. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2446-6_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Midlöv, Patrik, Tommy Eriksson, and Annika Kragh. "Quality of Care in the Elderly." In Drug-related problems in the elderly, 21–35. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2446-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Midlöv, Patrik, Tommy Eriksson, and Annika Kragh. "Inappropriate Drugs in the Elderly." In Drug-related problems in the elderly, 37–47. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2446-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Midlöv, Patrik, Tommy Eriksson, and Annika Kragh. "Drugs and Common Health Conditions in Old Age." In Drug-related problems in the elderly, 49–78. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2446-6_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Drug related problems (DRPs)"

1

AlAzmi, Aeshah, Omaima Ahmed, Rph Hani ALHamdan, Hana AlGarni, Rawan AlZain, Rihad Althubaiti, Mohammed Aseeri, and Adnan AlShaikh. "54 Epidemiology of preventable drug-related problems (DRPs) in hospitalized children: single institution observational study." In Patient Safety Forum 2019, Conference Proceedings, Kingdom of Saudi Arabia, Ministry of National Guard Health Affairs. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/bmjoq-2019-psf.54.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

AlAzmi, Aeshah, Rph Hani AlHamdan, Omaima Ahmed, Prog Steve Tomlin, and Asia Rashed. "53 The impact of a computerized physician order entry (CPOE) system on the incidence and nature of drug-related problems (DRP) in pediatric wards in king abdulaziz medical city – jeddah." In Patient Safety Forum 2019, Conference Proceedings, Kingdom of Saudi Arabia, Ministry of National Guard Health Affairs. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/bmjoq-2019-psf.53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

JANCA, ALEKSANDAR, OYE GUREJE, and LINDA A. BENNETT. "ASSESSMENT OF ALCOHOL- AND DRUG-RELATED PROBLEMS IN DIFFERENT CULTURES." In IX World Congress of Psychiatry. WORLD SCIENTIFIC, 1994. http://dx.doi.org/10.1142/9789814440912_0121.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lee, Vivian WY. "26 Managing drug-related problems in advanced heart failure patients." In 1st Asia Pacific Advanced Heart Failure Forum (APAHFF), 15th December 2017, Hong Kong. BMJ Publishing Group Ltd, British Cardiovascular Society and Asia Pacific Heart Association, 2018. http://dx.doi.org/10.1136/heartasia-2018-apahff.26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Barceló-Vidal, J., N. Carballo, M. De Antonio-Cuscó, X. Fernández-Sala, D. Echeverría-Esnal, P. Acín, C. López-Mula, et al. "4CPS-384 Potential drug related problems in the time of COVID-19." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.216.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Requejo, C. Caballero, C. García-Molina Sáez, A. Trujillano Ruiz, M. Onteniente Candela, M. Gil Candel, E. Urbieta Sanz, and P. Piñera Salmerón. "CP-133 Drug related problems in emergency department patients: role of clinical pharmacist." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ponjee, G., H. Van De Meerendonk, M. Janssen, and F. Karapinar-Çarkit. "5PSQ-155 The effect of geriatric stewardship on drug-related problems after discharge." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.588.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Onteniente Candela, M., I. Salar Valverde, M. Gil Candel, C. Pastor Mondéjar, C. Iniesta Navalón, C. Caballero Requejo, M. García Coronel, and E. Urbieta Sanz. "5PSQ-128 Pharmacotherapeutic profile and risk of drug-related problems and drug interactions in HIV+ patients of a health area." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.561.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Blanc, AL, B. Guignard, A. Desnoyer, O. Grosgurin, C. Marti, C. Samer, and P. Bonnabry. "CP-029 Pim-check used by physicians to reduce drug related problems in internal medicine." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Santos, Paulo, Patricia Oliveira, Beatriz Kaippert, Gabriella Gomes, Adriana Duarte, Monique Pimenta, Alessandra Bogio, Maria Maia, Renata Sousa, and Linda Boukai. "Current challenge in pharmacovigilance at Bio-Manguinhos/Fiocruz: detection of drug related problems in social media." In III Seminário Anual Científico e Tecnológico de Bio-Manguinhos. Instituto de Tecnologia em Imunobiológicos, 2016. http://dx.doi.org/10.35259/isi.sact.2016_28298.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Drug related problems (DRPs)"

1

Ni, Xiaofeng, Chunsong Yang, Yumei Bai, Zixian Hu, and Lingli Zhang. Drug-Related Problems of Patients in Primary Heath Care Institutions: a Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2021. http://dx.doi.org/10.37766/inplasy2021.6.0081.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Norsworthy, Sarah, Rebecca Shute, Crystal M. Daye, and Paige Presler-Jur. National Institute of Justice’s Forensic Technology Center of Excellence 2019 National Opioid and Emerging Drug Threats Policy and Practice Forum. Edited by Jeri D. Ropero-Miller and Hope Smiley-McDonald. RTI Press, July 2020. http://dx.doi.org/10.3768/rtipress.2020.cp.0011.2007.

Full text
Abstract:
The National Institute of Justice (NIJ) and its Forensic Technology Center of Excellence (FTCoE) hosted the National Opioid and Emerging Drug Threats Policy and Practice Forum on July 18–19, 2019, in Washington, DC. The forum explored ways in which government agencies and programs, law enforcement officials, forensic laboratory personnel, medical examiners and coroners, researchers, and other experts can cooperate to respond to problems associated with drug abuse and misuse. Panelists from these stakeholder groups discussed ways to address concerns such as rapidly expanding crime laboratory caseloads; workforce shortages and resiliency programs; analytical challenges associated with fentanyl analogs and drug mixtures; laboratory quality control; surveillance systems to inform response; and policy related to stakeholder, research, and resource constraints. The NIJ Policy and Practice Forum built off the momentum of previous stakeholder meetings convened by NIJ and other agencies to discuss the consequences of this national epidemic, including the impact it has had on public safety, public health, and the criminal justice response. The forum discussed topics at a policy level and addressed best practices used across the forensic community.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Drug related problems (DRPs)' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography